Hiroya Taniguchi Selected Research

Gastrointestinal Neoplasms (Gastrointestinal Cancer)

1/2023	Efficacy of Targeted Trials and Signaling Pathway Landscape in Advanced Gastrointestinal Cancers From SCRUM-Japan GI-SCREEN: A Nationwide Genomic Profiling Program.
11/2021	SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors.
12/2020	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
11/2020	Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
1/2019	A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroya Taniguchi Research Topics

Disease

63	Colorectal Neoplasms (Colorectal Cancer) 03/2024 - 10/2013
48	Neoplasms (Cancer) 10/2023 - 10/2008
21	Stomach Neoplasms (Stomach Cancer) 10/2021 - 06/2010
9	Colonic Neoplasms (Colon Cancer) 01/2023 - 10/2008
8	Neutropenia 11/2023 - 01/2017
8	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2016
5	Febrile Neutropenia 11/2023 - 01/2017
5	Microsatellite Instability 01/2023 - 01/2020
5	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023 - 01/2019
4	Adenocarcinoma 10/2023 - 01/2018
4	Disease Progression 01/2023 - 08/2011
3	Diarrhea 11/2020 - 08/2015
3	Esophageal Neoplasms (Esophageal Cancer) 10/2016 - 08/2011
2	Squamous Cell Carcinoma of Head and Neck 03/2024 - 12/2011
2	Mucositis 11/2020 - 08/2015
2	Sarcopenia 10/2018 - 06/2017
2	Nausea 01/2017 - 09/2016
2	Esophageal Squamous Cell Carcinoma 10/2016 - 08/2015
2	Prostatic Neoplasms (Prostate Cancer) 02/2011 - 11/2008
1	Nasopharyngeal Carcinoma 03/2024
1	Rectal Neoplasms (Rectal Cancer) 01/2023
1	Cutaneous Fistula 08/2022
1	Fistula 08/2022
1	Lymphatic Metastasis 04/2022
1	Leiomyosarcoma 12/2021

Drug/Important Bio-Agent (IBA)

21	Bevacizumab (Avastin)FDA Link 01/2024 - 02/2014
18	Irinotecan (Camptosar)FDA LinkGeneric 11/2023 - 06/2010
17	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2023 - 08/2012
15	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2014
14	Fluorouracil (Carac)FDA LinkGeneric 03/2024 - 08/2012
12	trifluridine tipiracil drug combinationIBA 01/2024 - 01/2017
10	Cetuximab (Erbitux)FDA Link 03/2024 - 09/2015
10	Circulating Tumor DNAIBA 01/2023 - 12/2020
9	Leucovorin (Folinic Acid)FDA Link 03/2023 - 08/2012
9	regorafenibIBA 01/2021 - 01/2017
8	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 04/2009
6	Immune Checkpoint InhibitorsIBA 12/2021 - 01/2020
6	Panitumumab (Vectibix)FDA Link 06/2021 - 03/2016
6	ErbB Receptors (EGF Receptor)IBA 06/2021 - 04/2015
4	pembrolizumabIBA 03/2024 - 01/2020
4	Trastuzumab (Herceptin)FDA Link 01/2023 - 08/2017
4	NivolumabIBA 12/2021 - 11/2018
4	human ERBB2 proteinIBA 11/2021 - 08/2017
4	RamucirumabIBA 10/2021 - 01/2019
4	AntibodiesIBA 01/2019 - 01/2017
3	Growth Factor ReceptorsIBA 01/2023 - 03/2016
3	Capecitabine (Xeloda)FDA Link 12/2021 - 01/2021
3	Taxoids (Taxanes)IBA 01/2020 - 08/2012
3	BilirubinIBA 01/2019 - 01/2016
3	S-1 plus cisplatinIBA 08/2014 - 08/2012
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2011 - 10/2008
3	LigandsIBA 02/2011 - 10/2008
2	binimetinibIBA 03/2024 - 01/2020
2	encorafenibIBA 03/2024 - 01/2020
2	Gemcitabine FDA Link 03/2024 - 04/2009
2	Cell-Free Nucleic AcidsIBA 01/2024 - 10/2023
2	pertuzumabIBA 01/2023 - 11/2021
2	Monoclonal AntibodiesIBA 01/2023 - 06/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2021 - 01/2018
2	Cytotoxins (Cytolysins)IBA 04/2020 - 08/2017
2	Antineoplastic Agents (Antineoplastics)IBA 03/2020 - 10/2012
2	Alanine Transaminase (SGPT)IBA 01/2020 - 01/2017
2	taxaneIBA 01/2019 - 09/2017
2	PlatinumIBA 11/2018 - 12/2011
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2017 - 01/2017
2	Docetaxel (Taxotere)FDA Link 08/2015 - 04/2009
1	B7-H1 AntigenIBA 03/2024
1	Angiogenesis InhibitorsIBA 01/2024
1	DNA (Deoxyribonucleic Acid)IBA 10/2023
1	Trifluridine (Viroptic)FDA LinkGeneric 01/2023
1	Notch ReceptorsIBA 10/2022
1	TAS-116IBA 12/2021
1	quinone (benzoquinone)IBA 11/2021
1	Oxidoreductases (Dehydrogenase)IBA 11/2021
1	napabucasinIBA 11/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2021
1	NAD (NADH)IBA 11/2021
1	Vascular Endothelial Growth Factor DIBA 10/2021
1	Tumor Biomarkers (Tumor Markers)IBA 07/2021
1	fms-Like Tyrosine Kinase 3IBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 03/2020
1	TropomyosinIBA 03/2020
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2020
1	Lipase (Acid Lipase)FDA Link 01/2020

Therapy/Procedure

42	Drug Therapy (Chemotherapy) 03/2024 - 04/2009
36	Therapeutics 03/2024 - 11/2008
6	Adjuvant Chemotherapy 01/2023 - 04/2015
3	Immunotherapy 09/2022 - 02/2020
3	Neoadjuvant Therapy 08/2022 - 08/2015
3	Combination Drug Therapy (Combination Chemotherapy) 01/2020 - 06/2010
3	Chemoradiotherapy 10/2016 - 08/2011
2	Hepatectomy 10/2021 - 08/2021
2	Drug Tapering 06/2017 - 08/2015
1	Ileostomy 08/2022
1	Colectomy 08/2022
1	Aftercare (After-Treatment) 04/2022
1	Lymph Node Excision (Lymph Node Dissection) 04/2022
1	Precision Medicine 11/2021
1	Radiotherapy 01/2020